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ABSTRACT 
   RET single nucleotide polymorphisms (SNPs) are associated with the Hirschsprung’s 
disease (HSCR). We investigated whether the amount of RET expressed in the ganglionic gut 
of human was dependent on the genotype of three regulatory SNPs (-5G>A rs10900296 and 
-1A>C rs10900297 in the promoter, and C>T rs2435357 in intron 1). We examined the 
effects of three regulatory SNPs on the RET gene expression in 67 human ganglionic gut 
tissues using quantitative real-time PCR.  Also, 315 Chinese HSCR patients and 325 
ethnically matched controls were genotyped for the 3 SNPs by polymerase chain reaction 
(PCR) and direct sequencing.  The expression of RET mRNA in human gut tissue did indeed 
correlate with the genotypes of the individuals.  The lowest RET expression was found for 
those individuals homozygous for the three risk alleles (A-C-T /A-C-T), and the highest for 
those homozygous for the “wild type” counterpart (G-A-C/G-A-C), with expression values 
ranging from 218.32±125.69 (mean±SE) in tissues from individuals carrying G-A-C/G-A-C 
to 31.42±8.42 for individuals carrying A-C-T /A-C-T  (p=0.018).  As expected, alleles -5A, 
-1C and intron 1 T were associated with HSCR (p=5.94x10-31, 3.12x10-24 and 5.94x10-37, 
respectively) as was the haplotype encompassing the three associated alleles (A-C-T) when 
compared to the wild type counterpart G-A-C (χ2=155.29, p<<0.0001). To our knowledge, 
this is the first RET expression genotype-phenotype correlation study conducted on human 
subjects to indicate common genetic variants in the regulatory region of RET may play a role 
in mediating susceptibility to HSCR, by conferring a significant reduction of the RET 
expression.  
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INTRODUCTION 
Hirschsprung’s disease (HSCR, OMIM 142623), which occurs in 1 in 5000 live births 
worldwide and most prevalently in Asians (2.8 per 10,000 life birth), is a developmental 
disorder characterized by the absence of ganglion cells of the plexus myentericus and 
submucosus in the variable lengths of the digestive tract (1,2).  Aganglionosis is attributed 
to a defect of the enteric nervous system (ENS), whereby neural crest cells (enteric neurons 
precursors) fail to innervate the lower gastrointestinal tract during embryonic development.  
This results in failure to pass meconium, chronic severe constipation and colonic distention in 
the neonatal period. HSCR most commonly presents sporadically although it can be familial 
and manifests with low, sex-dependent penetrance and variability in the length of the 
aganglionic segment (total, long and short segment aganglionosis) (2).  
HSCR has a complex genetic etiology, and the manifestation of the disease has been 
associated with mutations in genes that encode signaling molecules crucial for the proper 
ENS development.  The receptor tyrosine kinase gene, RET, which is mainly expressed in 
neural crest cells (NCC) during enteric neurogenesis and is required for normal development 
of the ENS, is the major susceptibility gene for HSCR (1-3).  Mutations in the coding 
sequences (CDSs) of the RET gene account for up to 50% of familial HSCR patients and 
7%–35% of sporadic cases (4-8).  Mutations leading to HSCR also occur in other genes 
involved in ENS development, namely ECE1, EDN3, EDNRB, GDNF, NRTN, SOX10, 
ZFHX1B, PHOX2B, GFRA1, TCF4, NTRK3, NRG1 and KIAA1279 (9-12).  However, the 
fact only a fraction of HSCR patients are accounted for mutations in these genes suggests that 
other susceptibility loci exist. However, the fact that only a fraction of HSCR patients are 
accounted for mutations in these genes suggests that other susceptibility loci exist.  In fact, 
additional HSCR loci have been mapped to the 9q31, 3p21, 19q12 and 16q23 chromosomal 
regions (11).  
Page 3 of 23 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 4 
The HSCR phenotype is also associated with RET single nucleotide polymorphisms 
(SNPs) spanning throughout the gene.  These could act as low-susceptibility factors and/or 
modifiers (13-18). Current in vitro data suggests that HSCR-associated RET regulatory SNPs 
might contribute to HSCR by decreasing RET expression.  Our previous study showed that 
alleles -5A and -1C (-5 and -1 bp from the transcription start site) of the promoter 
polymorphisms -5G>A and -1A>C (rs10900296 and rs10900296 respectively; 
HSCR-associated allele underlined throughout the text) were strongly associated with HSCR 
in Chinese (19).  Using firefly luciferase transcription reporter assays on cell lines, we also 
showed that these two HSCR-associated RET polymorphisms disrupted a TTF1-binding site 
and decreased transcription from the RET promoter.  Similarly, the same two promoter SNPs 
were found to be associated with HSCR in the Italian, German, Dutch, French and Spanish 
populations (15,20-24).  Importantly, we showed that the frequency of the risk alleles, -5A 
and -1C, was much higher in our population than in European, providing an insight for the 
higher incidence of HSCR in Chinese.  In another study, Emison and colleagues identified 
another HSCR-associated RET SNP within a conserved enhancer-like sequence in intron 1 
(C>T rs2435357) (25). Likewise, a markedly reduced RET enhancer activity was noted in 
vitro.  Interestingly, the frequency of rs2435357 was found to be more elevated in East-Asia 
than in other populations and the authors also correlated this fact with the higher incidence of 
HSCR in that region.  Although promoter and intron 1 HSCR-associated SNP alleles were 
reported to play an important role in the pathogenesis of HSCR by decreasing RET 
expression when tested in vitro, little in vivo evidence has been provided to sustain this 
hypothesis.  Since the physical distance between the promoter and the intron 1 SNPs is 
around 21 Kb, an attempt to test the combined effect of these 3 SNPs in the luciferase 
reporter assay is likely to be technically challenging.   
In this study, we sought to investigate the molecular basis of HSCR susceptibility by 
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 5 
studying the effect of the three HSCR-associated RET SNPs (individually and in combination) 
by quantitating the amount of RET expressed in the ganglionic part of the gut of HSCR 
patients or other newborn patients who had undergone colon surgery for reasons other than 
HSCR.  In addition, we re-evaluated the contribution of the genotypes and haplotypes of 
these RET regulatory polymorphisms in an extended sample that consisted of 315 HSCR 
patients and 325 controls.   
 
RESULTS 
RET expression is reduced in gut tissue from individuals carrying HSCR-associated 
RET SNPs   
We first investigated the potential effects of RET -5G>A, -1A>C and intron 1 C>T SNPs 
on the RET transcriptional activity by real-time RT-PCR quantitation of RET mRNA in 
ganglionic gut tissues (Figure 1) of HSCR patients and non-HSCR individuals.   
We analysed the RET expression in all tissue samples collected (N=67; HSCR and 
non-HSCR tissues) to establish a correlation between the expression level and the RET 
genotypes or diplotypes.  The expression of RET in gut tissue did indeed correlate with the 
genotypes of the individuals tested.  For rs2435357 in intron 1, the lowest RET expression 
was found for those individuals homozygous for the T risk allele and the highest for those 
homozygous for the “wild type” counterpart CC (Figure 1A).  The amount of RET mRNA 
(mean±SE) in individuals with the CC, CT and TT genotypes were 211.29±111.07 (N=9), 
58.94±13.18 (N=20) and 31.42±8.42 (N=38), respectively (p=0.012).  Moreover, there were 
no statistically significant difference between HSCR patients and non-HSCR individuals 
bearing the same genotype.  The mRNA expression values of the CC, CT and TT genotypes 
were 116.78±58.62, 59.49±14.58, 10.78±9.09 in HSCR patients and 258.54±106.09, 
56.49±14.58, 10.01±3.87 in non-HSCR individuals (p=0.583, 0.913 and 0.957 for each 
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 6 
genotype).  An allele-dosage effect in the reduction of RET expression was observed as 
expression values decreased according to the genotypes comprising the “T” HSCR-associated 
allele.  The effect of RET -5G>A or -1A>C on RET expression was similar to that of intron 
1 (data not shown).  We further compared the RET level of expression as a function of the 
3-site diplotypes.  The correlation diplotype-levels of RET expression followed the pattern 
described above for the intron 1 SNP, with individuals homozygous for the HSCR 
non-associated RET haplotye having the highest levels of RET expression (Figure 1B) and 
individuals homozygous for the RET risk diplotype having the lowest.  RET mRNA 
expression values were 218.32±125.69 (mean±SE) for individuals homozygous for the 
non-HSCR associated RET haplotype (G-A-C/G-A-C; N=8); 58.14±13.18 for individuals 
with only one risk haplotype (A-C-T/others; N=20) and 31.42±8.42 for individuals 
homozygous for the risk haplotype (A-C-T /A-C-T; N=38) (p=0.018).  The only individual 
with the diplotype A-C-C/A-C-C was not included in the analysis.  Again, the values 
obtained clearly indicate a dosage-dependent effect of the HSCR-associated RET haplotypes 
on the reduction of RET expression. 
 
Genotypes and diplotypes associated with HSCR 
We then re-evaluated the contribution of the genotypes and haplotypes of these RET 
regulatory polymorphisms in an extended sample that consisted of 315 HSCR patients and 
325 controls.  Having the functional consequences of these three SNPs in vivo, we next 
examined the association of them with risk of HSCR.  The genotypes for the three SNPs 
tested are shown in Table 1.  The allele frequencies for promoter -5A, -1C and intron 1 T 
alleles were 0.500, 0.645 and 0.0451 in controls, compared with 0.832, 0.900 and 0.827 in 
cases, respectively.  The observed genotype frequencies of all 3 polymorphisms, -5G>A, 
-1A>C and intron 1 C>T, in controls conformed to the Hardy-Weinberg equilibrium (p=0.947, 
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 7 
0.991 and 0.392, respectively).  The three RET SNPs were found to be in strong linkage 
disequilibrium, with a D’ value of 0.98 for -5G>A and -1A>C (p<0.001), 0.98 for -1A>C and 
intron 1 C>T (p<0.001), and 0.95 for -5G>A and intron1 C>T (p<0.001) in our study 
population. 
The frequencies for the intron 1 CC, CT, and TT genotypes differed considerably 
between cases and controls (χ2=162.54, p=5.94x10-37), with the frequency of TT 
homozygotes being much higher in cases than in controls (72.4% versus 19.1%).  The 
differences in genotype frequencies between cases and controls at the -5G>A and -1A>C 
sites were also highly significant (χ2=33.83, p=5.94x10-31 and χ2=103.14, p=3.12x10-24), 
although not as strong as those of intron 1 site.  
Since the there may be synergistic effects among these SNPs on the gene expression, 
we further analyzed the association with HSCR of the haplotypes comprising the three 
regulatory HSCR-associated SNP.  The haplotype and diplotype frequencies are presented in 
Table 2.  The haplotype A-C-T, was highly associated with an increased risk to HSCR 
(χ2=155.29, p<<0.0001).   
The genetic data is fully concordant with the RET expression data in human gut, where, 
as explained above, levels of RET expression correlated with the number of copies of 
HSCR-associated RET alleles. 
 
DISCUSSION 
It has been well recognized that RET, the major HSCR susceptibility gene, plays a 
crucial role in the normal ENS development (4,26).  Here, we have shown, for the first time, 
that individuals harboring RET HSCR-associated alleles have reduced RET expression in the 
ganglion cells of the gut, backing the initial genetic association data on these RET regulatory 
SNPs.  Thus, RET regulatory SNPs may confer an increased risk of HSCR by interfering 
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 8 
with the normal RET expression in human developing gut.  Diminished RET expression as a 
risk factor for HSCR may not only be due to inactivating CDS RET mutations but also to 
regulatory polymorphisms.  Uesaka and colleagues have shown in mice that reduced Ret 
expression recapitulated the genetic and phenotypic features of HSCR (27). Importantly, they 
show that other developmental processes also dependent on Ret function, such as kidney 
formation and motor innervations to the latissimus dorsi muscle, remained intact.  This 
illustrates that the effect of a low expression of RET is tissue-specific, as only the developing 
colon was implicated.  This argues for a tissue-specific regulation by trans-acting regulatory 
proteins only present in the developing gut.  Conceivably, DNA alterations in RET cis-acting 
elements targeted by tissue-specific transcription factors and/or long-range interacting 
proteins can indeed lead to tissue-specific dysregulation of RET.  This would most likely be 
associated with a substantial degree of inter-individual variability in the genetic 
predisposition to HSCR. 
 Our real-time RT-PCR quantitation of RET mRNA in human ganglionic gut tissues 
showed that the amount of RET mRNA form the enteric neurons correlated with the different 
genotypes and haplotypes of the three regulatory RET SNPs tested.  The lowest RET 
expression corresponded to individuals carrying the RET risk genotypes and the highest to 
those carrying the wild type genotypes.  This observation was independent of the HSCR 
disease status of the individual.  Even though the number of non-HSCR individuals was 
small, no statistically significant difference between HSCR patients and non-HSCR 
individuals bearing the same genotype was observed.  This is not surprising as these 
HSCR-associated RET SNPs are not exclusive of the HSCR patient group and represent one 
of several risk factors of HSCR.  As a complex disease, additional factors may be needed for 
the HSCR phenotype to appear, including the presence of and/or interaction with other yet 
unknown risk or protective alleles.  Thus, even though some non-HSCR individuals may 
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 9 
have reduced RET expression, this alone may not have been enough for the disease 
manifestation.  Importantly, as shown in Table 1, the number of cases with RET risk alleles 
outnumber by far that of controls.  The genetic analysis presented in this study clearly shows 
that the implication of these risk haplotypes in HSCR is in an autosomal recessive or dosage 
dependent manner.  The latter is fully concordant with the results of the RET expression 
study in human gut, which clearly indicates a dosage-dependent effect as the reduction in 
RET expression is more acute in individuals homozygous for the risk haplotype when 
compared to the heterozygous ones.  As over 70% of the HSCR patients are homozygous for 
the HSCR-associated RET haplotype (A-C-T) and most of the individuals with only one 
A-C-T haplotype belong to the control group (50.8% vs. 22.5% in HSCR patients), one would 
be conclude that levels of RET expression in individuals heterozygous for this RET haplotype 
reach the threshold required for the correct RET signaling, hence for the proper development 
of the enteric nervous system.  Heterozygosis for A-C-T among patients, could be explained 
by the presence of other risk alleles.  Yet, it is also tempting to speculate that differential 
RET allelic expression (due to either parental or other effects) between heterozygous patients 
and controls (expression mainly from the HSCR-associated RET allele in patients and mainly 
from the RET wild type allele in controls) could account for the genetic observation.  This 
could only be proven by comparing RET expression levels between a large collection of 
HSCR and non-HSCR tissue samples from heterozygous individuals.  Also important, if 
sample size permitted, would be to investigate the differences in RET levels of expression 
among individuals bearing only (in homozygosis or heterozygosis) one of the three risk SNPs.  
This would help elucidate if the reduction in RET expression levels is due to a joint effect of 
the three SNPs or to just to one of them (as seen in supplementary table 2, there is only one 
tissue sample homozygous for the promoter risk alleles and for the intron 1 wild type alleles).   
This study has limitations, some of which cannot be overcome.  Firstly, the gut of 
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 10 
newborn patients is in an advanced developmental stage (although not fully mature).  Thus 
our analysis does not mimic the expression of RET during the early developmental stages of 
the human gut, when expression patterns of other genes may be different.  For obvious 
reasons, this cannot be surmounted.  Through this study we show that RET expression is 
already defective in the enteric neurons of the ganglionic part of the bowel for those 
individuals with the RET risk alleles.  Why and how this deficient expression leads to 
hypo- or aganglionosis of the adjacent tissue is yet to know.  Most likely, the aganglionic 
gut results from a gradual depletion of RET deficient enteric neurons, as they cannot fully 
respond to the environmental clues.  Secondly, also for obvious reasons, it is not possible to 
obtain gut tissue samples from controls, having to resort to use samples from individuals 
that for reasons other than HSCR underwent gut biopsy.  Thirdly, would be the sample size 
issue.  Due to the differences in genotype frequencies between cases and controls and also 
due to the preponderance of homozygous individuals for the risk alleles among patients, it is 
difficult to get a balanced representation of all genotypes and a desirable sample size.   
It is worth mentioning the work by Griseri and colleagues on lymphoblasts of selected 
individuals (18). That study also suggests a low expression from the RET promoter with the 
-5A rs10900296 and -1C rs10900297 risk alleles.   
Here, we provide the first genotype-phenotype correlation on RET expression levels in 
HSCR.  HSCR-associated RET regulatory SNPs play a critical role in the pathogenicity of 
the disease by affecting the expression of RET in the enteric neurons of the human gut.  Also, 
the study emphasizes the importance of RET gene dosage in the susceptibility of HSCR.   
 
MATERIALS AND METHODS 
Study subjects 
A total of 315 ethnic Chinese patients diagnosed with sporadic HSCR and 325 
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 11 
population control individuals were included in the case-control study.  All patients were 
histologically confirmed with either biopsy or surgical resection material for absence of 
enteric plexuses, and had been consecutively recruited in the University of Hong Kong Queen 
Mary Hospital and in the Beijing Children’s Hospital since January 1997.  Fifteen patients 
were affected with total colonic aganglionosis (TCA), 28 with long-segment aganglionosis 
(LSA) and 272 with short-segment aganglionosis (SSA) (Supplementary Table 1).  Part of 
the patients (172) had been participants in a molecular epidemiological study of HSCR 
previously described (19,28).  In this study, we expanded the sample size of the HSCR 
patients to 315 and that of the controls to 325.  Normal control subjects were unselected, 
unrelated, ethnic Chinese subjects without a diagnosis of HSCR whose samples were 
obtained from the blood bank of the Hong Kong Red Cross. 
Gut tissue was collected from 49 HSCR patients (subset of the 315 individuals 
genotyped) and 18 non-HSCR patients who had undergone colon surgery for reasons other 
than HSCR.   
At recruitment, informed consent was obtained from each subject.  This study was 
approved by the institutional review board of the University of Hong Kong (UW 03-227 
T/227).  
 
Polymorphism analysis  
Genomic DNA from 325 controls and 266 HSCR patients was extracted from blood 
samples by using a QIAamp-Blood kit (Qiagen, Hilden, Germany), as previously described 
(19,28). For 49 HSCR patients, DNA was isolated from surgically resected tissues.  
Genotypes were analyzed using PCR and direct sequencing as described below performed 
without knowledge of case-control status of subjects.  A 15% masked, random sample of 
cases and controls was tested twice by different persons, and the results were concordant for 
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 12 
all of the masked duplicate sets.  
The PCR primers and PCR and sequencing conditions for amplification of the RET 
intron 1 region containing the polymorphism rs2435357C>T are available upon request.  
The other two polymorphisms, including rs10900296 A>G, rs10900297 A>C, which are 
located at -1bp and -5bp from the RET transcription start site, were analyzed by PCR and 
direct sequencing as previously described (19).  
 
Real-time assay for gene expression 
Resected colon tissues were collected from forty-nine HSCR patients and 18 non-HSCR 
patients.  These individuals had no CDS RET mutations that could cofound our experiment.  
No tissues were available from the rest of the patients.  HSCR diagnosis was confirmed by 
haematoxylin-eosin and acetylcholinesterase histochemical staining of rectal biopsies.  For 
the 18 non-HSCR patients (9 affected with imperforate anus; 7 with necrotizing enterocolitis 
and 2 with mesenteric cysts), tissues were obtained from at least 2cm away from the margin 
of the diseased bowel.  The frequencies of genotypes and haplotypes of these three SNPs in 
human gut tissues are presented in the supplementary Tables 2 and 3.  All resected tissues 
were immediately placed in liquid nitrogen and then stored at –80oC before analysis.  
Full-thickness tissues from ganglionic portions of bowel of each HSCR patients and colons 
from non-HSCR patients were used for RNA extraction by Trizol Reagent (Life Technologies, 
Rockville, MD) and converted to cDNA using an oligo (dT)15 primer and Superscript III 
(Invitrogen, Carlsbad, CA).  The cDNA products equivalent to 10ng of total RNA were used 
for quantitative real-time PCR which was performed by ready-to-use TaqMan gene 
expression assays from Applied Biosystems.  Although RET is mainly expressed in ENS 
cells and their precursors, recent reports indicate that RET is also expressed and involoved in 
the development of lymphoid system of the human gut, such in Peyer’s patches (29). 
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 13 
Therefore we used a general neuronal marker, PGP9.5, as internal control to make sure that 
the RET transcripts detected were from enteric neurons.  The assay for RET was 
Hs01120027_ml and that for the neuron-specific gene PGP9.5 was Hs00188233_ml 
(endogenous control).  Real-time PCR was performed in triplicate (96-well plates) on an 
ABI 7700(Applied Biosystems) machine using standard thermal cycling conditions (10min at 
95oC, 40 cycles for 15s at 95oC, 1min at 6oC).  A standard curve was constructed for each 
PCR run with 10-fold serial dilutions containing 100, 10, 1, 0.1 and 0.01ng/mL of cDNA 
from the cell line HTB11.  The amount of target gene per sample was interpolated according 
to the standard curves.  All analyses were performed in a blinded fashion with the laboratory 
operators unaware of genotyping data.   
 
Statistical analysis 
Allele, genotype and haplotypes frequency comparisons between the 315 patients 
and the 325 control individuals were performed using Chi-square tests and 
Cochran-Armitage test, which is typically used in tests for trend when some categories are 
ordered, therefore we used to detect the dosage dependent effect of RET variants in the risk 
of HSCR.  Chi-square tests were also performed to determine whether each polymorphism 
was in Hardy-Weinberg equilibrium within each group.  The program PHASE, which 
allows for recombination and decay of LD with distance, was used for computational 
reconstruction of most likely haplotype pairs for each individual, for estimation of the 
haplotype frequencies in each group, and case-control global statistics (30,31). Linkage 
disequilibrium was analyzed using Haploview software (32).   
Statistical comparisons of the normalized RET gene expression between the different 
genotypes or haplotypes were performed with one-way ANOVA.  These statistical analyses 
were done using the SPSS statistics software package (SPSS, Chicago, IL).  All statistical 
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tests were two-sided, and p<0.05 was considered significant. 
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FIGURE LEGEND 
 
Figure 1.  Associations between genetic variants in the regulatory region and normalized 
RET expression in the colon tissues from the normal portions of HSCR patients and 
non-HSCR patients.  (Y axis represented the RET expression relative to PGP9.5) 
(A) Significant difference of normalized RET expression were observed among CC, CT 
and TT genotypes of intron 1 polymorphism (P =0.012, one-way ANOVA). 
(B) Significant difference of normalized RET expression were observed among different 
diplotypes ((-5G>A; -1A>C; intron 1C>T) of RET variants (P =0.018, one-way ANOVA).  
Graphs represent mean ± SE. 
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Table 1: Genotype distribution of the RET gene polymorphisms (percentage of individuals in brackets) 
Polymorphism Genotypes Patients n = 315 Controls n = 325 X2 (Yates correction); P  
-5G>A a GG 17 (5.4) 81 (24.9) reference 
 GA 72 (22.9) 163 (50.2) 5.58; 0.018 
 AA 226 (71.7) 81 (24.9) 95.67; <<0.0001 
Deviation from Hardy-Weinberg equilibrium P = 0.0011 P = 0.95  
-1A>C b AA 9 (2.9) 41 (12.6) reference 
 AC 45 (14.3) 149 (45.8) 0.36; 0.549 
 CC 261 (82.9) 135 (41.5) 40.67; <<0.0001 
Deviation from Hardy-Weinberg equilibrium P = 0.0003 P = 0.99  
Intron 1 C>T c CC 22 (7.0) 95 (29.2) reference 
 CT 65 (20.6) 169 (52.0) 2.91; 0.088 
 TT 228 (72.4) 62 (19.1) 123.38; <<0.0001 
Deviation from Hardy-Weinberg equilibrium P = 0.0000007 P = 0.39  
a
 p=5.94x10-31, Cochran-Armitage test  
b
 p=3.12 x10-24, Cochran-Armitage test  
c
 p=5.94x10-37, Cochran-Armitage test 
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Table 2: Frequencies and counts of RET haplotypes and diplotypes comprising -5G>A, -1A>C and intron1 C>T 
 
Haplotypes  Patients (630 chromosomes) Controls (650 chromosomes) χ2 (Yates correction); P  
 (-5; -1; intron 1) % counts % counts  
G-A-C  9.8 62 34.9 227 reference 
G-C-C  7.0 44 17.1 111 0.70; 0.40 
A-C-C  1.4 9 2.6 17 1.67; 0.19 
A-C-T  81.8 515 34.9 285 155.29; <<0.0001 
Diplotypes Patients (315 subjects)           Controls (325 
subjects) 
 
G-A-C/G-A-C a 2.9 9 12.0 39 reference 
G-A-C/others a 2.2 7 14.8 48 0.32; 0.57 
G-A-C/ A-C-T a 11.7 37 31.1 101 0.85; 0.36 
others/ A-C-T a 10.8 34 19.7 64 3.21; 0.07 
A-C-T / A-C-T a 70.5 222 18.5 60 67.43; <<0.0001 
others b/others b 1.9 6 4.0 13 0.66; 0.42 
 
a
 p <<0.0001, Cochran-Armitage test 
b
 represented nor G-A-C or A-C-T  haplotypes 
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Abbreviations 
HSCR: Hirschsprung’s disease; SNP: single nucleotide polymorphism; RET: receptor tyrosine kinase; NCC: neural crest cell; ENS: enteric 
nervous system 
 
Page 22 of 23Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
R
E
T
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
R
E
T
A B
N= 8 N= 20 N= 38N= 9 N= 20 N= 38
Page 23 of 23 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
